The main objective of the call is to produce clinical evidence and economic data that could help make the case for blood biomarker implementation in a healthcare setting in the UK.
Disease-modifying treatments are around the corner, but it simply won’t matter if we cannot diagnose people with dementia in a timely and accurate manner. It is estimated that right now only 2% of people with dementia in the UK would be eligible to access a treatment.
Blood biomarkers can be the answer to this problem.
This grant is funded by Alzheimer’s Research UK, Alzheimer’s Society and the National Institute for Health and Care Research (NIHR), and generously supported by the players of the People’s Postcode Lottery.
For more information on the Blood Biomarker Call, and potential areas of study, please read the Request for Applications.
This programme will fund a prospective project (duration 4-5 years) that assesses a panel of biomarkers in real-world populations in the UK.
In this call we are partnering with the Biomarker Factory at the UK Dementia Research Institute (UKDRI) at UCL.
In order to build a stronger case for future implementation, the final proposal should include a component of an economic analysis of the use of blood biomarkers in a healthcare setting.
The successful applicants will be required to work closely with the Policy and Influencing teams at Alzheimer’s Society and Alzheimer’s Research UK, both during the project and after completion, to work towards the implementation of blood biomarkers in healthcare settings where the findings of the project support this.
Applicants do not need to budget for this workstream in their proposals.
Visit funding web page